These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 11342466

  • 21. Delivery of factor VIII gene into skeletal muscle cells using lentiviral vector.
    Jeon HJ, Oh TK, Kim OH, Kim ST.
    Yonsei Med J; 2010 Jan; 51(1):52-7. PubMed ID: 20046514
    [Abstract] [Full Text] [Related]

  • 22. Mechanism of the immune response to human factor VIII in murine hemophilia A.
    Wu H, Reding M, Qian J, Okita DK, Parker E, Lollar P, Hoyer LW, Conti-Fine BM.
    Thromb Haemost; 2001 Jan; 85(1):125-33. PubMed ID: 11204564
    [Abstract] [Full Text] [Related]

  • 23. Expression of human factor VIII by splicing between dimerized AAV vectors.
    Chao H, Sun L, Bruce A, Xiao X, Walsh CE.
    Mol Ther; 2002 Jun; 5(6):716-22. PubMed ID: 12027555
    [Abstract] [Full Text] [Related]

  • 24. Long-term expression of human coagulation factor VIII in a tolerant mouse model using the φC31 integrase system.
    Chavez CL, Keravala A, Chu JN, Farruggio AP, Cuéllar VE, Voorberg J, Calos MP.
    Hum Gene Ther; 2012 Apr; 23(4):390-8. PubMed ID: 22077817
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice.
    Nguyen GN, Lindgren JR, Seleme MC, Kafle S, Zander CB, Zheng XL, Sabatino DE.
    J Thromb Haemost; 2023 Aug; 21(8):2101-2113. PubMed ID: 37080538
    [Abstract] [Full Text] [Related]

  • 27. Suppression of the immune response to FVIII in hemophilia A mice by transgene modified tolerogenic dendritic cells.
    Su RJ, Epp A, Feng J, Roy J, Latchman Y, Wu X, Bolgiano D, Josephson NC.
    Mol Ther; 2011 Oct; 19(10):1896-904. PubMed ID: 21772255
    [Abstract] [Full Text] [Related]

  • 28. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
    Ishiwata A, Mimuro J, Mizukami H, Kashiwakura Y, Takano K, Ohmori T, Madoiwa S, Ozawa K, Sakata Y.
    J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver.
    Park F, Ohashi K, Kay MA.
    Blood; 2000 Aug 01; 96(3):1173-6. PubMed ID: 10910939
    [Abstract] [Full Text] [Related]

  • 31. An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs.
    Sun J, Shao W, Chen X, Merricks EP, Wimsey L, Abajas YL, Niemeyer GP, Lothrop CD, Monahan PE, Samulski RJ, Nichols TC, Li C.
    Mol Ther Methods Clin Dev; 2018 Sep 21; 10():257-267. PubMed ID: 30140713
    [Abstract] [Full Text] [Related]

  • 32. Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice.
    Ye P, Thompson AR, Sarkar R, Shen Z, Lillicrap DP, Kaufman RJ, Ochs HD, Rawlings DJ, Miao CH.
    Mol Ther; 2004 Jul 21; 10(1):117-26. PubMed ID: 15233948
    [Abstract] [Full Text] [Related]

  • 33. Efficient stabilization of recombinant human coagulation factor VIII in the milk of transgenic mice using hFVIII and vWF co-expression vector transduction.
    Ren X, Gong X, Cai Q, Guo X, Xu M, Ren Z, Zeng Y.
    Biotechnol Lett; 2015 Jun 21; 37(6):1187-94. PubMed ID: 25700825
    [Abstract] [Full Text] [Related]

  • 34. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.
    Fong S, Yates B, Sihn CR, Mattis AN, Mitchell N, Liu S, Russell CB, Kim B, Lawal A, Rangarajan S, Lester W, Bunting S, Pierce GF, Pasi KJ, Wong WY.
    Nat Med; 2022 Apr 21; 28(4):789-797. PubMed ID: 35411075
    [Abstract] [Full Text] [Related]

  • 35. Investigation of hFVIII production in mammary glands of transgenic mice.
    Mohammadian T, Rassi H.
    Monoclon Antib Immunodiagn Immunother; 2014 Oct 21; 33(5):325-9. PubMed ID: 25358000
    [Abstract] [Full Text] [Related]

  • 36. Lack of germline transmission in male mice following a single intravenous administration of AAV5-hFVIII-SQ gene therapy.
    Fonck C, Su C, Arens J, Koziol E, Srimani J, Henshaw J, Van Tuyl A, Chandra S, Vettermann C, O'Neill CA.
    Gene Ther; 2023 Aug 21; 30(7-8):581-586. PubMed ID: 35132205
    [Abstract] [Full Text] [Related]

  • 37. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
    Long BR, Veron P, Kuranda K, Hardet R, Mitchell N, Hayes GM, Wong WY, Lau K, Li M, Hock MB, Zoog SJ, Vettermann C, Mingozzi F, Schweighardt B.
    Mol Ther; 2021 Feb 03; 29(2):597-610. PubMed ID: 33309883
    [Abstract] [Full Text] [Related]

  • 38. Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia A.
    Greig JA, Smith MK, Nordin JML, Goode T, Chroscinski EA, Buza EL, Schmidt N, Kattenhorn LM, Wadsworth S, Wilson JM.
    Hum Gene Ther; 2022 Apr 03; 33(7-8):421-431. PubMed ID: 34652966
    [Abstract] [Full Text] [Related]

  • 39. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA, Gallo-Penn A, Andrews J, Idamakanti N, Kaleko M, Connelly S.
    Hum Gene Ther; 2001 Sep 01; 12(13):1651-61. PubMed ID: 11535168
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of the activity levels of rat FVIII and human FVIII delivered by adeno-associated viral vectors both in vitro and in vivo.
    Zhang W, Mao J, Shen Y, Zhang G, Shao Y, Ruan Z, Wang Y, Wu W, Wang X, Zhu J, Chen S, Xiao W, Xi X.
    Blood Cells Mol Dis; 2018 Nov 01; 73():47-54. PubMed ID: 30249384
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.